CHRISTOPHER DINGESS: Open Payments
NPI 1982016192 · KELLER, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,063 in 58 payments from 19 companies in 2025. Trend: 2023 $1,868 · 2024 $1,571 · 2025 $1,063
Food & beverage: $1,063
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 14 | $258 |
| Novo Nordisk Inc | 6 | $109 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $78 |
| Lilly USA, LLC | 4 | $76 |
| Abbott Laboratories | 3 | $70 |
| PFIZER INC. | 3 | $59 |
| Astellas Pharma US Inc | 3 | $57 |
| Amgen Inc. | 3 | $45 |
| AstraZeneca Pharmaceuticals LP | 2 | $31 |
Products named: VRAYLAR, REXULTI, CAPLYTA, MOUNJARO, Ozempic, NURTEC ODT, Veozah, QULIPTA.
Industry payments across TX — which companies pay providers there.
